The Metabolic Consequences of Ferritin Excess and Deficiency, and Clinical Strategies for Optimizing Iron Status
Introduction
Perimenopause is increasingly recognized as a period of profound metabolic change, including, but extending well beyond, reproductive hormone fluctuations. While shifts in estrogen and progesterone receive substantial attention, an important and often overlooked physiologic transition occurring during midlife is alteration in iron metabolism.
Throughout the reproductive years, menstruation creates a predictable route of iron loss that shapes iron balance in women. As menstrual cycles become irregular, lighter or heavier, more prolonged, and eventually cease during the menopausal transition, this mechanism of iron elimination that has occurred since puberty changes substantially.
For some women, years of heavy or prolonged bleeding result in progressive iron depletion and ferritin deficiency. As the ovaries ovulate less regularly but estrogen levels remain closer to normal, the thickness of the uterine lining can increase due to the lack of progesterone-mediated thinning, leading to greater iron loss. For others, declining estrogen means a thinner lining, lighter menstrual flow, and more erratic cycles. Less menstrual blood loss in these women permits accumulation of iron stores, reflected by rising serum ferritin concentrations. Increasing evidence suggests that these changes may influence insulin sensitivity, oxidative stress, body composition, hepatic health, cardiovascular risk, cognitive function, and overall metabolic aging.
Importantly, both ends of the spectrum – too little iron and excessive iron storage – may produce overlapping symptoms including fatigue, hair loss, exercise intolerance, sleep disturbance, mood changes, and cognitive complaints. This creates diagnostic challenges for clinicians and increases the importance of accurate assessment and individualized management.
For naturopathic doctors, understanding changes in iron physiology during perimenopause offers an opportunity to move beyond simplistic interpretations of ferritin values and to evaluate iron status within the broader context of inflammation, metabolism, hormonal transition, and whole-person care.
What Is Meant by “Iron Dysregulation”?
Iron dysregulation refers to disruption of normal iron balance, sometimes resulting in insufficient iron availability, excessive iron accumulation, impaired iron utilization, or abnormal distribution of iron between tissues and circulation.
Under healthy physiologic conditions, iron balance is tightly controlled because humans possess highly limited mechanisms for active iron excretion. Daily regulation therefore occurs primarily through adjustment of intestinal absorption, recycling of old red blood cells, and storage and release from tissues under the control of the hepatic hormone hepcidin.
Iron dysregulation may manifest in several distinct ways:
Iron deficiency
Reduction in total body iron stores that may progress to impaired red blood cell production and iron deficiency anemia.
Functional iron deficiency
Adequate or elevated iron stores with inadequate availability to tissues due to impaired mobilization, commonly mediated by inflammation and elevated hepcidin.
Iron overload
Excess accumulation of body iron that exceeds physiologic requirements and promotes oxidative stress and tissue injury.
Dysmetabolic hyperferritinemia
Dysmetabolic hyperferritinemia is elevated ferritin levels associated with insulin resistance, obesity, metabolic dysfunction, inflammation, or hepatic steatosis, without classic hereditary iron overload.
These states should not be viewed as isolated conditions. Iron participates directly in mitochondrial energy production, hemoglobin production (oxygen transport), thyroid hormone synthesis, neurotransmitter production, immune regulation, collagen formation, and cellular antioxidant systems. Consequently, iron dysregulation can present with systemic and multisystem effects.
Perimenopause represents a uniquely vulnerable period for iron dysregulation because women may transition rapidly from decades of chronic iron loss into relative iron retention, often while simultaneously developing changes in insulin sensitivity, body composition, inflammatory tone, and hepatic metabolism.
Why Iron Status Changes During Perimenopause
The menopausal transition introduces several physiologic changes that alter iron handling:
- Menstrual blood loss becomes irregular, sometimes light or excessive, sometimes prolonged and eventually declines.
- Average body iron stores begin to rise.
- Ferritin concentrations increase across the transition.
- Hepcidin signalling changes in response to reduced iron loss and altered inflammatory status.
- Visceral adiposity (belly fat) and insulin resistance become more common.
- Hepatic iron storage may increase alongside development of metabolic dysfunction.
Observational studies demonstrate that ferritin concentrations rise significantly across menopause and that this rise is associated with worsening markers of insulin resistance independent of aging alone. This observation has led investigators to propose that iron accumulation may contribute to aspects of cardiometabolic aging in women.
However, interpretation requires caution: elevated ferritin does not automatically indicate iron overload. Ferritin is also an acute-phase reactant and may increase in response to inflammation, obesity, nonalcoholic fatty liver disease (NAFLD or MASLD), alcohol intake, infection, or chronic disease. Likewise, normal hemoglobin does not exclude clinically meaningful iron deficiency.
For naturopathic doctors, the key question is not simply whether ferritin is high or low, but whether iron physiology is functioning appropriately.
In the sections that follow, we will review the physiology of iron regulation, the mechanisms linking ferritin excess and deficiency to metabolic outcomes in perimenopause, and evidence-based strategies for assessment and treatment.
Iron Physiology Relevant to Perimenopause: Hepcidin, Ferritin, Ferroportin and Menopause-Related Changes in Iron Handling
To understand iron dysregulation in perimenopause, we must first recognize that iron homeostasis differs fundamentally from that of most nutrient systems. Unlike sodium, potassium, glucose, or calcium, humans possess almost no regulated pathway for active iron excretion. Daily iron balance therefore depends almost entirely on the control of absorption, storage, recycling, and tissue distribution.
Because iron is simultaneously essential and potentially toxic in excess, iron metabolism is governed through highly coordinated regulatory systems that maintain adequate tissue availability while minimizing oxidative injury.
Iron Absorption and Distribution
Total body iron stores average approximately 2-4 g in adult women, with the majority distributed among:
- Hemoglobin within erythrocytes (~65-70%)
- Iron storage proteins (ferritin and hemosiderin)
- Myoglobin in skeletal muscle
- Iron-containing enzymes involved in mitochondrial energy production and metabolism
Dietary iron is absorbed primarily in the small intestine and exists in two major forms:
Heme Iron
Derived from animal foods and absorbed more efficiently through dedicated transport mechanisms.
Non-heme Iron
Derived primarily from plant foods and fortified foods and requires reduction and transport processes before absorption.
Once absorbed into enterocytes, iron has two possible fates:
- Temporary intracellular storage as ferritin
- Export into circulation via ferroportin
After export, circulating iron binds to transferrin, the primary transport protein responsible for delivering iron to tissues.
Transferrin-bound iron supports:
- Red blood cell production
- Thyroid hormone synthesis
- Mitochondrial ATP production
- Neurotransmitter synthesis
- Immune function
- Cellular antioxidant defence systems
Under normal conditions, transferrin remains only partially saturated, limiting free circulating iron and reducing oxidative damage.
Hepcidin: The Master Regulator of Iron Homeostasis
Although iron absorption occurs in the intestine, systemic iron regulation is controlled primarily by hepcidin, a peptide hormone synthesized in the liver.
Hepcidin acts as the body’s central “iron gatekeeper.”
Its primary target is ferroportin – the only known cellular iron exporter.
Ferroportin is expressed on:
- Gut lining cells
- White blood cells known as macrophages
- Liver cells
- Placental cells
When hepcidin levels rise:
- Ferroportin is internalized and degraded
- Dietary iron absorption decreases
- Stored iron becomes trapped within cells
- Serum iron concentrations fall
When hepcidin levels decline:
- Ferroportin activity increases
- Iron absorption rises
- Stored iron is mobilized into circulation
This system allows rapid adaptation to physiologic conditions.
Major Stimulators of Hepcidin Production
| Stimulus | Physiologic Effect |
|---|---|
| Increased iron stores | Hepcidin decreases further absorption |
| Inflammation (especially IL-6) | Sequesters iron |
| Infection | Restricts iron availability to disease-causing pathogens |
| Obesity and metabolic dysfunction | Promotes functional iron restriction |
Major Suppressors of Hepcidin Production
| Stimulus | Physiologic Effect |
|---|---|
| Iron deficiency | Suppressed Hepcidin increases absorption |
| Blood loss | Mobilizes stored iron |
| Hypoxia | Enhances iron availability |
| Increased erythropoiesis | Supports red blood cell production |
This hepcidin–ferroportin axis becomes highly relevant during perimenopause because changing menstrual patterns alter one of the major physiologic signals regulating iron balance.
Ferritin: More Than an Iron Storage Marker
Ferritin is often interpreted clinically as synonymous with iron stores, but ferritin performs multiple biologic roles.
Ferritin is an intracellular storage protein capable of safely containing thousands of iron atoms within a biologically inert structure.
Its primary functions include:
- Iron storage
- Prevention of oxidative damage
- Regulation of intracellular iron availability
Small amounts circulate in serum and correlate broadly with total body iron stores.
However, ferritin is also an acute-phase reactant. This means that inflammatory signalling, particularly IL-6 and other cytokines, can increase ferritin independent of actual iron overload.
This distinction becomes clinically important because elevated ferritin may reflect:
- Increased body iron
- Liver inflammation
- Obesity
- Metabolic syndrome
- Nonalcoholic fatty liver disease (NAFLD or MASLD)
- Infection
- Chronic inflammatory conditions
As a result, ferritin should rarely be interpreted in isolation.
Iron Recycling: The Hidden Driver of Iron Availability
Only approximately 1-2 mg of dietary iron is absorbed daily under normal conditions.
By contrast, approximately 20-25 mg of iron is recycled each day from aging red blood cells, where it gets released back into circulation via ferroportin.
This recycling process supplies most of the iron required for ongoing red blood cell production. Inflammation can disrupt this system.
During inflammatory states:
- Hepcidin rises
- Iron becomes trapped within white blood cells (macrophages)
- Serum iron falls
- Ferritin may rise
- Functional iron deficiency develops
This mechanism explains why patients may experience fatigue, hair loss, and low transferrin saturation despite apparently “normal” or elevated ferritin levels.
Menopause-Related Changes in Iron Physiology
The reproductive years create a unique iron environment characterized by repeated iron depletion through menstrual blood loss.
Perimenopause progressively alters this physiology.
As cycles become less predictable, women may alternate between periods of:
- substantial iron loss from heavy bleeding,
- and periods of reduced iron elimination.
Eventually, menstrual cessation removes a major route of iron excretion entirely.
Several mechanisms likely contribute:
Reduced Iron Loss
Decreased cumulative menstrual blood loss allows gradual expansion of iron stores.
Increased Adiposity and Inflammation
Visceral adiposity (belly fat) contributes to low-grade inflammation and altered hepcidin signalling.
Metabolic Dysfunction
Insulin resistance and hepatic steatosis (fatty liver) may promote iron retention and elevate ferritin.
Oxidative Stress
Iron accumulation may increase reactive oxygen species generation and impair mitochondrial function.
Clinically, this transition may, to some extent, explain why fatigue, hair changes, insulin resistance, sleep disturbance, and metabolic symptoms often become more prominent during midlife.
Understanding these physiologic shifts establishes the foundation for appropriately interpreting ferritin levels and identifying when elevated or low iron markers reflect true dysregulation rather than normal menopausal adaptation.
Ferritin Excess in Perimenopause: Iron Overload, Hyperferritinemia, Oxidative Stress and Insulin Resistance
As women transition through perimenopause, increasing ferritin concentrations are frequently observed in clinical practice. Historically, this rise has often been interpreted as a benign consequence of aging or cessation of menstruation. However, emerging evidence suggests that elevated ferritin during midlife may have broader implications for metabolic health.
For naturopaths, one of the greatest challenges is distinguishing physiologic increases in iron stores from pathologic hyperferritinemia and determining whether elevated ferritin is a marker, a mediator, or a consequence of metabolic dysfunction.
Importantly, ferritin excess and true iron overload are not synonymous.
Ferritin Elevation Does Not Necessarily Mean Iron Overload
Ferritin serves multiple biologic roles and increases under several physiologic and pathophysiologic conditions.
Elevated ferritin may reflect:
Increased iron stores
Examples:
- Reduced menstrual blood loss
- Excess iron supplementation
- Repeated transfusions
- Hereditary hemochromatosis
Inflammatory signaling
Examples:
- Obesity
- Chronic inflammatory disorders
- Infection
- Autoimmune disease
Metabolic dysfunction
Examples:
- Insulin resistance and associated Dysmetabolic Iron Overload Syndrome
- MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease, previously NAFLD)
Hepatic injury
Examples:
- Alcohol-associated liver injury
- Hepatic steatosis (fatty liver)
- Viral hepatitis
For this reason, ferritin should always be interpreted alongside:
- Transferrin saturation (TSAT, Saturation or %Sat)
- CBC
- Serum iron
- TIBC
- hs-CRP
- Liver enzymes
- Metabolic markers
Clinical interpretation based on ferritin alone may substantially overestimate iron overload.
Dysmetabolic Hyperferritinemia: An Emerging Midlife Pattern
One increasingly recognized phenotype among perimenopausal and postmenopausal women is dysmetabolic hyperferritinemia.
This pattern is generally characterized by:
- Elevated ferritin
- Normal or mildly elevated transferrin saturation
- Central adiposity
- Hyperinsulinemia
- Elevated triglycerides
- Hepatic steatosis
- Low-grade inflammation
Unlike hereditary hemochromatosis, total body iron burden may be only mildly increased, yet metabolic consequences can still be substantial.
Several mechanisms may contribute:
Chronic Low-Grade Inflammation
Adipose tissue releases inflammatory cytokines that stimulate ferritin production and alter iron handling.
Altered Hepcidin Signalling
Obesity and insulin resistance appear to modify hepcidin regulation, reducing normal iron trafficking.
Hepatic Iron Retention
Metabolic dysfunction may promote accumulation of iron within hepatocytes and the reticulo-endothelial system.
Oxidative Stress
Iron catalyzes formation of reactive oxygen species that may amplify inflammation, insulin resistance and tissue injury.
This has led investigators to propose that ferritin may act not simply as a marker of metabolic disease, but potentially as a contributor to metabolic progression.
Iron as a Driver of Oxidative Stress
Iron is essential for mitochondrial respiration and energy production, but excess unbound iron can become biologically damaging.
Through the Fenton reaction, iron catalyzes the conversion of hydrogen peroxide into highly reactive oxygen species.
Potential downstream consequences include:
- Lipid peroxidation
- DNA damage
- Mitochondrial dysfunction
- Endothelial injury
- Impaired cellular signaling
- Accelerated tissue aging
These mechanisms are especially relevant during perimenopause because estrogen normally exerts antioxidant, anti-inflammatory, and mitochondrial-protective effects. As estrogen declines, oxidative defences may weaken while iron availability simultaneously increases.
This combination has been proposed as one contributor to accelerated metabolic aging during the menopausal transition.
Ferritin and Insulin Resistance: A Bidirectional Relationship
Among the most clinically relevant areas of investigation is the relationship between iron and glucose metabolism.
Numerous observational studies have demonstrated associations between elevated ferritin and:
- Higher fasting insulin
- Increased HOMA-IR
- Greater visceral adiposity
- Increased risk of type 2 diabetes
- Higher prevalence of metabolic syndrome
Several biologic mechanisms may explain this relationship.
Iron-Induced Insulin Resistance
Iron excess may contribute to insulin resistance through:
- Oxidative damage to insulin signalling pathways
- Mitochondrial dysfunction
- Increased hepatic glucose production
- Adipose tissue inflammation
- Reduced insulin sensitivity
Iron Effects on Pancreatic Beta Cells
Beta cells possess relatively limited antioxidant defences.
Excess iron exposure may:
- Increase oxidative injury
- Impair insulin secretion
- Reduce beta-cell survival
Hyperinsulinemia May Further Increase Ferritin
The relationship also appears bidirectional.
Elevated insulin concentrations may:
- Promote hepatic ferritin synthesis
- Alter iron storage
- Increase inflammatory signalling
This creates a potential feed-forward cycle:
Increasing ferritin → oxidative stress → insulin resistance → greater ferritin accumulation.
Although causality remains under investigation, this framework helps explain why ferritin often tracks with worsening metabolic health during midlife.
Iron Excess and Cardiometabolic Risk
Iron accumulation has also been investigated as a contributor to cardiovascular disease.
Proposed mechanisms include:
- Endothelial dysfunction
- Increased LDL oxidation
- Arterial stiffness
- Vascular inflammation
- Impaired nitric oxide signalling
Studies have linked elevated ferritin with:
- Hypertension
- Metabolic syndrome
- Coronary artery disease
- Increased cardiovascular risk markers
Interpretation remains complex because inflammation likely contributes to both elevated ferritin and cardiovascular disease risk.
Nonetheless, ferritin may offer useful clinical insight when interpreted alongside traditional metabolic markers.
When Elevated Ferritin Warrants Further Investigation
In perimenopause, further evaluation should generally be considered when elevated ferritin is accompanied by:
- Elevated transferrin saturation
- Persistent liver enzyme elevation
- Strong family history of iron overload (hemachromatosis)
- Unexpected fatigue
- Arthralgia (joint pain)
- New onset of diabetes
- Hepatomegaly (liver enlargement)
- Hyperpigmentation
- Disproportionate metabolic dysfunction
Potential next steps may include:
- Repeat fasting iron studies
- Inflammatory markers
- Liver assessment
- HFE genotyping when clinically indicated
- Specialist referral
For many women, elevated ferritin reflects metabolic dysfunction rather than classic iron overload. Distinguishing these phenotypes allows treatment strategies to target the underlying driver rather than focusing exclusively on lowering ferritin.
Iron Deficiency in Perimenopause: Heavy Menstrual Bleeding, Functional Iron Deficiency, and Clinical Consequences Beyond Anemia
Although increasing ferritin concentrations and iron retention occur in many women during the menopausal transition, iron deficiency remains extremely common throughout perimenopause and should not be overlooked.
Perimenopause is characterized by fluctuating ovarian function, irregular ovulation, and altered patterns of uterine lining stimulation. These hormonal changes frequently result in abnormal uterine bleeding, creating periods of substantial iron loss that may persist for years before menopause occurs.
At the same time, chronic inflammation, obesity, gastrointestinal dysfunction, medication use, and altered iron regulation may impair iron absorption and utilization.
Consequently, women in perimenopause may experience iron deficiency despite appearing otherwise metabolically healthy, and importantly, symptoms often emerge well before anemia develops.
Why Iron Deficiency Remains Common During Perimenopause
The menopausal transition is associated with some of the highest rates of abnormal uterine bleeding across the female lifespan.
Anovulatory cycles become increasingly common as ovarian reserve declines. Without consistent ovulation and progesterone production, prolonged estrogen exposure may promote irregular endometrial proliferation and unpredictable shedding.
Patterns commonly reported include:
- Heavy menstrual bleeding
- Prolonged menstrual bleeding
- Frequent cycles
- Intermenstrual bleeding
- Unpredictable episodes of excessive blood loss
These menstrual changes may result in cumulative depletion of iron stores.
However, abnormal bleeding is only one contributor.
Additional factors affecting iron balance include:
Gynecologic Causes of Blood Loss
These conditions often correlate with the hormonal imbalances that are common at perimenopause:
- Uterine fibroids
- Adenomyosis
- Endometrial polyps
- Endometrial hyperplasia
- Intrauterine pathology
Gastrointestinal Contributors
These all impair the ability to absorb iron:
- Reduced gastric acid production
- Long-term proton pump inhibitor use
- Celiac disease
- Inflammatory bowel disease
- Chronic gastritis
Occult gastrointestinal bleeding (bleeding that you can’t see) may contribute to iron loss.
Dietary Contributors
- Low dietary iron intake
- Vegetarian or vegan dietary patterns without iron optimization
- Reduced protein intake
- Caloric restriction
Metabolic and Inflammatory Contributors
- Elevated hepcidin
- Obesity
- Chronic inflammation
- Functional iron sequestration
For naturopaths, identifying the underlying mechanism matters because treatment strategies differ substantially depending on whether deficiency results from true depletion versus impaired availability.
Iron Deficiency Without Anemia: A Clinically Important but Underrecognized State
One of the most important concepts in contemporary iron medicine is that clinically meaningful iron deficiency may exist before anemia develops.
Iron depletion generally progresses through stages:
Stage 1: Iron Store Depletion
- Ferritin declines
- Hemoglobin remains normal
Stage 2: Iron-Restricted Red Blood Cell Production
- Iron delivery to the bone marrow becomes inadequate
- Transferrin saturation decreases
- Early symptoms emerge
Stage 3: Iron Deficiency Anemia
- Hemoglobin declines
- Microcytosis develops (red blood cells become smaller)
- Oxygen delivery becomes impaired
Many women present during the first or second stage. Because hemoglobin is preserved initially, routine CBC testing may appear “normal,” creating false reassurance.
Clinically, patients may report:
- Fatigue
- Reduced exercise tolerance
- Brain fog
- Hair shedding
- Poor concentration
- Anxiety
- Sleep disruption
- Cold intolerance
- Palpitations
- Reduced stress resilience
Recognition of these earlier stages is particularly relevant in naturopathic practice because patients often seek care before overt disease develops.
Functional iron deficiency refers to a state in which iron stores are adequate, or occasionally elevated, but iron is not effectively delivered to tissues.
This pattern commonly occurs in association with:
- Chronic inflammation
- Obesity
- Autoimmune conditions
- Liver disease
- Metabolic syndrome
The mechanism is largely mediated through elevated hepcidin.
Inflammatory signalling increases hepcidin production, which:
- Suppresses intestinal iron absorption
- Reduces ferroportin activity
- Traps iron within macrophages
- Restricts circulating iron availability
Laboratory findings may include:
- Normal or elevated ferritin
- Low transferrin saturation
- Low serum iron
- Elevated inflammatory markers
- Variable CBC findings
Patients may therefore exhibit symptoms consistent with iron insufficiency despite reassuring ferritin values.
This pattern becomes particularly important in midlife women because obesity, insulin resistance, and inflammatory burden commonly increase during perimenopause.
Important Context
- Heavy bleeding should never automatically be attributed to “normal perimenopause.”
- Ferritin alone cannot distinguish iron deficiency from inflammatory iron restriction.
- Normal hemoglobin does not exclude symptomatic iron deficiency.
- Persistent low iron indices warrant investigation of bleeding, absorption, and inflammatory contributors.
- Correction of deficiency should include identification of the underlying cause—not simply replacement.
Understanding iron deficiency across its full spectrum establishes the foundation for evidence-based testing and individualized treatment strategies.
Laboratory Assessment: How to Evaluate Iron Status in Perimenopause Beyond Ferritin Alone
Ferritin measurement is valuable, but incomplete.
Because ferritin functions as both an iron storage protein and an acute-phase reactant, interpretation without additional laboratory context may lead to underdiagnosis of iron deficiency, overdiagnosis of iron overload, inappropriate supplementation, or missed inflammatory and metabolic contributors.
This challenge becomes particularly relevant in perimenopause, where menstrual variability, inflammation, insulin resistance, altered body composition, liver dysfunction, and changing iron physiology frequently coexist.
A more comprehensive laboratory approach allows naturopathic doctors to distinguish iron depletion, iron overload, functional deficiency, and inflammatory hyperferritinemia.
Start With a Foundational Iron Assessment
A practical first-line iron assessment panel generally includes:
- Complete blood count (CBC)
- Ferritin
- Serum iron
- Total iron-binding capacity (TIBC)
- Transferrin saturation (TSAT)
These tests evaluate different aspects of iron physiology and should be interpreted together rather than independently.
Ferritin: The Most Useful but Most Misinterpreted Marker
Ferritin remains the best available marker of body iron stores under low-inflammatory conditions.
General interpretation principles:
| Ferritin Pattern | Possible Interpretation |
|---|---|
| Low ferritin | Reduced iron stores |
| Normal ferritin | Adequate stores or masked deficiency |
| Elevated ferritin | Iron excess, inflammation, metabolic dysfunction, liver disease |
However, ferritin rises independently of iron in response to:
- IL-6 signaling
- Obesity
- NAFLD/MASLD
- Alcohol intake
- Infection
- Chronic disease
Clinicians should therefore resist assigning meaning to ferritin without evaluating iron availability.
Interpreting Low Ferritin
Low ferritin is generally highly specific for iron deficiency. Questions to ask when ferritin is low:
- Is bleeding contributing?
- Is intake adequate?
- Is absorption impaired?
- Is iron demand increased?
Interpreting High Ferritin
Questions to ask when ferritin is high:
- Is transferrin saturation elevated?
- Is CRP elevated?
- Are liver enzymes abnormal?
- Is metabolic syndrome present?
- Is there family history of iron overload?
Elevated ferritin should trigger investigation, not assumptions.
Serum Iron: Useful but Variable
Serum iron reflects the amount of iron bound to transferrin.
Limitations:
- Significant variation throughout the day
- Influenced by meals
- Influenced by inflammation
- Short-term fluctuations
For greatest consistency:
- Obtain fasting morning samples when feasible.
Low serum iron may occur with:
- Iron deficiency
- Inflammation
- Infection
- Chronic disease
High serum iron may occur with:
- Iron supplementation
- Iron overload
- Hemolysis
Serum iron alone should not guide treatment decisions.
Total Iron-Binding Capacity (TIBC)
TIBC estimates transferrin availability.
Typical patterns:
| Finding | Common Interpretation |
|---|---|
| High TIBC | Iron deficiency |
| Low TIBC | Inflammation, liver dysfunction |
Because transferrin production declines during inflammatory states, TIBC may become less reliable in chronic disease.
Transferrin Saturation (TSAT): A Critical Companion to Ferritin
TSAT estimates the percentage of transferrin occupied by iron.
Calculation:
TSAT (%) = (Serum iron ÷ TIBC) × 100
TSAT provides information about iron availability rather than storage.
Typical interpretation:
| TSAT Pattern | Clinical Interpretation |
|---|---|
| Low TSAT | Reduced circulating iron |
| Normal TSAT | Balanced availability |
| Elevated TSAT | Excess iron exposure or overload |
Ferritin and TSAT together often provide more clinically useful information than either marker alone.
Examples:
Pattern 1: Iron Deficiency
| Marker | Typical Finding |
|---|---|
| Ferritin | Low |
| TSAT | Low |
| TIBC | High |
| CBC | Variable |
Pattern 2: Functional Iron Deficiency
| Marker | Typical Finding |
|---|---|
| Ferritin | Normal or elevated |
| TSAT | Low |
| CRP | Elevated |
Pattern 3: Iron Overload
| Marker | Typical Finding |
|---|---|
| Ferritin | Elevated |
| TSAT | Elevated |
Pattern 4: Dysmetabolic Hyperferritinemia
| Marker | Typical Finding |
|---|---|
| Ferritin | Elevated |
| TSAT | Normal or mildly elevated |
| Metabolic markers (like fasting insulin) | Abnormal |
Pattern recognition often provides greater clinical insight than isolated reference ranges.
Step 2: Add Contextual Testing When Needed
Additional testing may improve diagnostic accuracy in complex presentations.
High-Sensitivity C-Reactive Protein (hs-CRP)
Useful for:
- Interpreting ferritin in inflammatory states
- Identifying occult inflammatory burden
Liver Enzymes (ALT, AST, GGT)
Useful for:
- Assessing NAFLD/MASLD
- Identifying hepatic contributors to ferritin elevation
Fasting Insulin and HbA1c
Useful for:
- Evaluating metabolic contributors
- Identifying dysmetabolic hyperferritinemia
Soluble Transferrin Receptor (sTfR)
Useful for:
- Distinguishing iron deficiency from inflammation
- Identifying tissue-level iron demand
General interpretation:
- Elevated sTfR supports iron deficiency
- Less influenced by inflammation than ferritin
Reticulocyte Hemoglobin Content
Emerging utility:
- Reflects recent iron availability for making red blood cells
- May detect deficiency earlier than hemoglobin
Hepcidin (Emerging Marker – not readily available)
Potential applications:
- Distinguishing absorption versus sequestration disorders
- Predicting response to iron therapy
Current limitations:
- Limited standardization
- Restricted clinical availability
Clinical Decision-Making: Interpreting the Whole Patient
Laboratory assessment should ultimately answer four questions:
- Is total body iron low, normal, or elevated?
- Is iron reaching tissues appropriately?
- Is inflammation altering interpretation?
- What is driving the dysregulation?
For naturopathic doctors, iron testing becomes most valuable when interpreted alongside:
- Menstrual history
- Dietary patterns
- GI function
- Metabolic status
- Body composition
- Liver health
- Inflammatory burden
- Symptoms
The goal is not simply normalization of ferritin levels; it is the restoration of appropriate iron physiology.
Clinical Strategies for Optimizing Iron Status: Evidence-Based Treatment of Iron Deficiency, Functional Iron Restriction, and Ferritin Excess
Management of iron dysregulation in perimenopause requires a phenotype-based approach rather than a uniform supplementation or depletion strategy. Treatment decisions should be guided by whether the clinical picture reflects true iron deficiency, functional iron restriction, or iron excess within a broader metabolic context.
Importantly, the same symptom profile—fatigue, hair loss, cognitive changes, reduced exercise tolerance—may occur in all three states, making laboratory confirmation essential before initiating therapy.
1. Treatment of Absolute Iron Deficiency
Absolute iron deficiency is characterized by depleted iron stores, typically reflected by low ferritin and reduced transferrin saturation, often in the context of ongoing blood loss or inadequate intake/absorption.
Primary Therapeutic Goals
- Replete iron stores
- Restore hemoglobin synthesis (if affected)
- Improve tissue oxygenation and mitochondrial function
- Address the underlying cause of iron loss
Oral Iron Therapy: First-Line Approach
Oral iron remains first-line for most patients without severe deficiency or intolerance.
Key considerations include:
Iron Formulation
- Ferrous salts (e.g., ferrous sulfate): often poorly tolerated
- Ferrous bisglycinate: improved gastrointestinal tolerability
- Heme iron polypeptide: higher bioavailability, less influenced by dietary inhibitors
- Liposomal iron: emerging option for improved tolerance
Dosing Strategy
Recent evidence supports alternate-day dosing over traditional daily high-dose therapy due to hepcidin-mediated absorption dynamics.
- Lower, intermittent dosing may improve fractional absorption
- Reduces gastrointestinal side effects
- Minimizes hepcidin-induced absorption blockade
Absorption Optimization
Iron absorption is enhanced by:
- Vitamin C co-administration
- Empty stomach administration (when tolerated)
- Avoidance of calcium, coffee, tea, and high-phytate meals near dosing
Absorption is reduced by:
- Proton pump inhibitors (PPIs)
- Hypochlorhydria (low stomach acid)
- High-calcium intake
- Polyphenols and phytates (found in grains, legumes and nuts)
Monitoring Response
A typical response pattern includes:
- Reticulocyte rise within 1-2 weeks
- Hemoglobin increase within 2-4 weeks (if anemic)
- Ferritin repletion over weeks to months. I would typically retest after 3 months of oral iron therapy.
Treatment should continue for several months after hemoglobin normalization to fully replenish stores.
Addressing the Root Cause
Without correction of the underlying driver, recurrence is common.
Common etiologies in perimenopause include:
- Heavy menstrual bleeding
- Uterine fibroids or adenomyosis
- Gastrointestinal blood loss
- Malabsorption syndromes
2. Functional Iron Deficiency (Iron Sequestration State)
Functional iron deficiency is characterized by impaired iron availability despite normal or elevated iron stores, typically mediated by inflammatory upregulation of hepcidin.
Primary Therapeutic Goals
- Reduce inflammatory signalling
- Improve iron mobilization
- Restore ferroportin function
- Avoid unnecessary iron loading
Key Clinical Principle
Iron supplementation alone may be ineffective or potentially counterproductive if hepcidin is elevated.
Targeted Interventions
Address Underlying Inflammation
Core contributors may include:
- Insulin resistance
- Adiposity and visceral fat
- Nonalcoholic fatty liver disease
- Chronic inflammatory conditions
Improving metabolic health often improves iron availability without direct iron therapy.
Dietary and Lifestyle Interventions
- Anti-inflammatory dietary patterns (e.g., low-carb Mediterranean-style approaches)
- Regular physical activity (improves insulin sensitivity and iron utilization)
- Weight reduction when appropriate
- Reduction of alcohol intake in hepatic dysfunction
Micronutrient Support
Nutrients involved in iron trafficking and erythropoiesis may include:
- Vitamin A (supports iron mobilization)
- Vitamin C (enhances absorption when iron is appropriate)
- B-complex vitamins (erythropoiesis support)
- Copper (iron transport and utilization)
Iron Supplementation Considerations
If supplementation is required:
- Lower dosing strategies may be preferred
- Monitor response carefully
- Avoid prolonged supplementation without reassessment
3. Iron Excess and Dysmetabolic Hyperferritinemia
Management of elevated ferritin depends on whether true iron overload is present or whether ferritin elevation reflects metabolic or inflammatory dysfunction.
Primary Therapeutic Goals
- Reduce excess iron burden (when present)
- Decrease oxidative stress
- Improve metabolic health and insulin sensitivity
- Address hepatic iron accumulation if applicable
Determine Whether True Iron Overload Exists
Key distinguishing feature:
- Elevated transferrin saturation suggests true iron overload
- Normal TSAT with elevated ferritin more often suggests dysmetabolic hyperferritinemia
4. Therapeutic Phlebotomy and Blood Donation
In cases of confirmed iron overload (including hereditary hemochromatosis or elevated TSAT with high ferritin), iron reduction strategies may be appropriate.
Mechanism
Phlebotomy reduces total body iron stores by removing circulating red blood cells, prompting mobilization of stored iron.
Clinical Considerations
- Should be guided by laboratory monitoring
- Frequency depends on ferritin trajectory and hemoglobin stability
- Contraindicated in iron deficiency or anemia
Even in non-hemochromatosis dysmetabolic hyperferritinemia, supervised blood donation may sometimes be considered, though evidence varies and clinical judgment is required. Naturopathic doctors in Ontario cannot order therapeutic phlebotomy; however, anyone can donate blood through the Canadian Red Cross, provided you meet their screening standards.
5. Metabolic and Hepatic-Focused Interventions
Because dysmetabolic hyperferritinemia is strongly associated with insulin resistance and hepatic steatosis, addressing metabolic dysfunction is central.
Insulin Sensitization
- Dietary pattern optimization
- Resistance training and aerobic exercise
- Reduction of refined carbohydrate intake
- Improvement of sleep quality and circadian rhythm
Hepatic Support
- Reduction of alcohol intake
- Weight management where indicated
- Nutritional strategies supporting hepatic fat reduction
Improvements in liver health often correlate with reductions in ferritin over time.
6. Antioxidant and Iron-Chelation Complementary Therapies
Certain nutrients and polyphenols have been studied for their ability to influence iron absorption or oxidative stress.
Potential adjunctive agents include:
- Curcumin (may reduce oxidative stress and influence iron regulation)
- Green tea catechins (reduce dietary iron absorption modestly)
- Quercetin (antioxidant and metal-binding properties)
- Polyphenol-rich dietary patterns
These should be considered supportive rather than primary therapies.
7. Key Clinical Safety Considerations
Iron is essential but potentially harmful in excess. Therefore:
- Iron supplementation should always be guided by laboratory evidence
- Ferritin alone is insufficient to determine treatment direction
- Iron overload should be confirmed before depletion strategies
- Functional deficiency should not be treated as absolute deficiency
8. Integrative Clinical Framework
A practical decision model for perimenopausal iron dysregulation:
Low ferritin + low TSAT
→ Absolute iron deficiency → Replace iron + investigate cause
Normal/high ferritin + low TSAT + inflammation
→ Functional deficiency → Treat inflammation first
High ferritin + high TSAT
→ Iron overload → Reduce iron burden (phlebotomy/donation)
High ferritin + normal TSAT + metabolic dysfunction
→ Dysmetabolic hyperferritinemia → Treat metabolic and hepatic drivers
This framework emphasizes that ferritin is not a treatment target in isolation, but rather one component of a broader physiologic system.
Clinical Takeaways for Perimenopausal Care: Reframing Iron as a Dynamic Metabolic Biomarker
Iron dysregulation in perimenopause is best understood not as a single deficiency-or-excess problem, but as a dynamic and shifting physiologic system influenced by reproductive aging, inflammation, metabolic health, and hepatic function.
For naturopathic doctors, this requires moving beyond static reference ranges and toward a functional interpretation of iron status within the broader endocrine-metabolic context.
Conclusion
Iron dysregulation in perimenopause represents a clinically significant but under-recognized contributor to metabolic and symptomatic burden in midlife women.
By integrating iron physiology with endocrine transition, inflammatory status, and metabolic health, clinicians can move beyond ferritin-centric interpretation toward a more precise and physiologically grounded model of care.
In doing so, iron becomes not merely a laboratory value to correct, but a dynamic biomarker reflecting the intersection of reproductive aging, metabolism, and systemic health.
References for Iron Dysregulation and Perimenopause
- Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023;74:261-277.
- Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500-510.
- Camaschella C. Iron deficiency. Blood. 2019;133(1):30-39.
- Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397(10270):233-248.
- Kim C, Nan B, Kong S, Harlow S. Changes in iron measures over menopause and associations with insulin resistance. J Womens Health (Larchmt). 2012;21(8):872-877.
- Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker. Metallomics. 2014;6(4):748-773.
- Vantyghem MC, Girardot C, Boulogne A, Wemeau JL. Iron overload and insulin resistance. Presse Med. 2005;34(19 Pt 1):1391-1398.
- Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843.
- Stoffel NU, et al. Iron absorption from supplements is greater with alternate day dosing. Lancet Haematol. 2017;4(11):e524–e533.
- Vantyghem MC, et al. Iron overload and insulin resistance. Presse Med. 2005;34(19 Pt 1):1391-1398.
- Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol. 2009;15(37):4617-4626.
- Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to ferritin in diagnosis of iron deficiency. Blood. 1997;89(3):1052-1057.
- Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013;87(2):98-104.
- Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulphate supplementation causes significant gastrointestinal side effects. PLoS One. 2015;10(2):e0117383.
- Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based guideline for restless legs syndrome and iron deficiency.
- Mleczko-Sanecka K, Silvestri L. Regulatory connections between iron and glucose metabolism. Acta Haematol. 2021;144(1):9-18.
- Lee SH, et al. Accelerated increase in ferritin levels during menopausal transition as a marker of metabolic health. Sci Rep. 2025;15:14295.
- Jiang R, et al. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004;291(6):711-717.
- Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51(8):2348-2354.
- Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.
